| Name | Title | Contact Details |
|---|
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.
MedCases Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.
Founded by Dr. Samuel Brown, Brown Fertility is a fully comprehensive fertility clinic offering patients exceptional results through personalized care and affordable treatment plans. With over 15 years experience and the management of more than 5,000 IVF cycles, Dr. Samuel Brown consistently achieves success rates above the national average. From basic evaluation and testing to the most advanced procedures and treatments available, Brown Fertility is dedicated to Conceiving Miracles™.
Over 26 million Americans suffer from chronic kidney disease (CKD), including 1.5 million New Yorkers. Formed in 1972 as a philanthropic gift of Edwin and Rhoda Sperber, the Foundation provides services to patients, family members, the general public and clinical and academic professionals throughout the Northeast. The mission of the Northeast Kidney Foundation is to improve the quality of life of those affected by kidney disease and related conditions through early identification, intervention, prevention and support services; to promote organ donation; and to empower those we serve to be an effective voice for better healthcare at the local, state and federal levels.